Hyperlipidemia is a risk factor for bladder cancer in young adult men: a population-based cohort study

Hung-Jen Shih, Ke-Hsun Lin, Yu-Ching Wen, Yen-Chun Fan, Pei-Shan Tsai, Chun-Jen Huang

Hung-Jen Shih
Wan Fang Hospital, Taipei Medical University

Ke-Hsun Lin
Wan Fang Hospital, Taipei Medical University

Yu-Ching Wen
Wan Fang Hospital, Taipei Medical University

Yen-Chun Fan
National Taipei University

Pei-Shan Tsai
Taipei Medical University

Chun-Jen Huang
Wan Fang Hospital, Taipei Medical University

huangcj1112@gmail.com Corresponding Author

Prescreen

10.21203/rs.3.rs-22267/v1

Subject Areas
Urology & Nephrology

Keywords

lipid, hyperlipidemia, bladder cancer, gender
Abstract

Background: A high-cholesterol diet increases the risk of bladder cancer. This study investigated whether hyperlipidemia is a risk factor for bladder cancer.

Methods: Data from Taiwan National Health Insurance Database were analyzed. The primary study end point was the occurrence of newly diagnosed bladder cancer. The relative risk of bladder cancer in a hyperlipidemia cohort was compared with that in an age- and gender-matched non-hyperlipidemia cohort.

Results: Our data revealed that the hyperlipidemia cohort had a significantly higher subsequent risk of bladder cancer than did the non-hyperlipidemia cohort (adjusted hazard ratio [HR]=1.37, \( P=0.005 \)) after propensity score adjustment. Subgroup analyses revealed that men in the hyperlipidemia cohort had a significantly higher subsequent risk of bladder cancer than did those in the non-hyperlipidemia cohort (adjusted HR=1.36, \( P=0.040 \)). However, the risk of bladder cancer was not significantly different between women in the hyperlipidemia cohort and those in the non-hyperlipidemia cohort. Subgroup analyses further revealed that the risk of bladder cancer was significantly higher in men aged 20–39 years in the hyperlipidemia cohort than in those in the non-hyperlipidemia cohort (adjusted HR=5.45, \( P=0.029 \)).

Conclusions: Hyperlipidemia is a risk factor for bladder cancer in young adult men.

Introduction

In 2012, bladder cancer was the ninth most commonly diagnosed cancer worldwide.\(^1\) Globally, the bladder cancer age-standardized incidence rates (per 100,000 person-years) are 9 for men and 2.2 for women and the age-standardized mortality rates (per 100,000 person-years) are 3.2 for men and 0.9 for women, respectively.\(^1,\)\(^2\) Similar pictures are observed in Taiwan.\(^1,\)\(^2\) In non–muscle-invasive bladder cancer, adjuvant treatment and long-term regular follow-up after transurethral resection of the bladder tumor are required to detect tumor recurrence and progression.\(^3\) In muscle-invasive bladder cancer, patients should receive radical cystectomy or tri-modality treatment for organ preservation.\(^4\) During 2007–2011, the survival rate for bladder cancer in Taiwan was approximately 67%.\(^2\) Identifying risk factors for bladder cancer is important and has profound clinical and epidemiological impacts.

The identified risk factors for bladder cancer include tobacco smoking,\(^5\) occupational exposure to aromatic amines and other chemicals,\(^1\) arsenic in drinking water,\(^2\) aristolochia-based herbal medicines,\(^2\) radiotherapy,\(^6\) and genetic factors.\(^7\) Tobacco smoking is a major risk factor for bladder cancer.\(^8\) A meta-analysis showed that tobacco smoking causes abnormalities in serum lipids, including an increase in triglycerides and a decrease in the high-density lipoprotein cholesterol level.\(^8\) A high-cholesterol diet increases the risks of various cancers, including bladder cancer.\(^9\) In a hospital-based case–control study, patients with metabolic syndrome had a two-fold higher risk of bladder cancer than did patients without metabolic syndrome.\(^10\)

Collectively, these data indicate an association between hyperlipidemia and the subsequent risk of bladder cancer. To elucidate this association, we conducted this population-based study and hypothesized that patients with hyperlipidemia may have a higher subsequent risk of bladder cancer than do patients without hyperlipidemia. Furthermore, hyperlipidemia in young adults increases the risk of coronary heart disease,\(^11\) and lipid metabolism differs by gender.\(^12\) Hyperlipidemia may have differential impacts in adults with different ages and genders. In this study, the risk of bladder cancer was thus further examined through subgroup analyses stratified by age and gender to determine whether the subsequent risk of bladder cancer is significantly different between men and women with hyperlipidemia.
Materials And Methods

Data sources
In this study, data retrieved from the Longitudinal Health Insurance Database 2010 (LHID2010) were analyzed. The single-payer National Health Insurance (NHI) program was established in Taiwan in 1995. Approximately 99.9% of the population of Taiwan is covered in the NHI program. The longitudinal medical records of all insurants in the NHI program are included in the National Health Insurance Research Database (NHIRD). One million people from the Registry of Beneficiaries of the NHIRD in 2010 (approximately 27.38 million individuals) were randomly sampled to create the LHID2010. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes are used for diagnoses in the database. The diagnostic accuracy of the NHI claims data with ICD-9-CM diagnostic codes have been validated by the National Health Research Institute, Taiwan. If malignancy is diagnosed, insurants can apply for a Catastrophic Illness Certificate, and the medical records, pathology, and imaging reports are validated by a panel of specialists. The LHID2010 includes the Registry of the Catastrophic Illness Patient Database and thus provides disease information for the purpose of research. Because the LHID2010 contains anonymous data, no patient consent is required. This study was approved by the Institutional Review Board of Taipei Medical University (Protocol Number: N201803071).

Study design
This study included individuals with at least two separate inpatient or outpatient medical records with hyperlipidemia diagnoses (ICD-9-CM code 272.x) between January 2000 and December 2012. In Taiwan, according to the diagnostic criteria for hyperlipidemia, physicians diagnose hyperlipidemia and prescribe medications for hyperlipidemia. In this study, the index date for the hyperlipidemia cohort was defined as the date of hyperlipidemia diagnosis. Individuals without hyperlipidemia were matched by age, gender, and the index date to patients with hyperlipidemia (index date ± 90 days) in a 1:1 ratio and were included in the control cohort. Patients who were aged younger than 20 years or older than 99 years, diagnosed as having hyperlipidemia or bladder cancer for only one occasion, or diagnosed as having hyperlipidemia or bladder cancer before the index date were excluded. Medical diagnoses were identified using ICD-9-CM codes, and medication use was identified according to Anatomical Therapeutic Chemical (ATC) classification system codes. The primary end point of this study was the occurrence of newly diagnosed bladder cancer. To identify all patients with bladder cancer, each patient was tracked from the index date until the end of 2013. To ensure the accuracy of bladder cancer diagnosis, the diagnosis code of bladder cancer (ICD-9-CM code 188.x) should be identified in at least two separate inpatient or outpatient medical records.

The confounders considered in this study were identified within 1 year before the index date. The comorbidities related to the risk of bladder cancer considered in this study were diabetes mellitus (DM) (ICD-9-CM code 250), hypertension (ICD-9-CM codes 401–405), obesity (body mass index > 27) (ICD-9-CM codes 278 and 278.0), chronic obstructive pulmonary disease (COPD) (as a proxy of smoking; ICD-9-CM codes 490–496), and uremia (ICD-9-CM code 586). Medications related to the risk of bladder cancer were aspirin (ATC codes B01AC06 and N02BA01), nonsteroidal anti-inflammatory drugs (NSAIDs) (ATC code M01A), metformin (ATC code A10BA02), rosiglitazone (ATC code A10BG02), and pioglitazone (ATC code A10BG03).

Statistical analyses
Distributions of patient characteristics, comorbidities, and medications as well as the incidence of bladder cancer were compared between the hyperlipidemia and non-hyperlipidemia cohorts by using chi-squared tests. Differences in the mean duration of bladder cancer development and median time of follow-up between these two cohorts were determined using the Mann–Whitney U test. A P value of less than 0.05 indicated statistical significance. The relative subsequent risk of bladder cancer in the hyperlipidemia cohort was compared with that in the non-hyperlipidemia cohort by using the Cox proportional hazards regression model. Cox regression analyses were further adjusted by the propensity score. The SPSS statistical package (SPSS 21.0, SPSS Inc., IBM
Corporation, Somers, NY, USA) was used for data analyses.

**Results**

**Demographics of study population**

A total of 67,110 patients were identified, with 33,555 patients in the hyperlipidemia cohort and 33,555 in the non-hyperlipidemia cohort (Fig. 1). The variables of age, DM, hypertension, obesity, COPD, uremia, aspirin use, NSAID use, metformin use, and rosiglitazone use were significantly different between these two cohorts (Table 1).
Table 1  
Demographic characteristics of hyperlipidemia and non-hyperlipidemia cohorts

|                  | Hyperlipidemia (n = 33555) | Non-hyperlipidemia (n = 33555) | P value \(^a\) |
|------------------|-----------------------------|-------------------------------|---------------|
| Age, n (%)       |                             |                               | 1.000         |
| 20–29            | 1598 (4.8)                  | 1598 (4.8)                    |               |
| 30–39            | 4544 (13.5)                 | 4544 (13.5)                   |               |
| 40–49            | 9220 (27.5)                 | 9220 (27.5)                   |               |
| 50–59            | 10149 (30.2)                | 10149 (30.2)                  |               |
| 60–69            | 5259 (15.7)                 | 5259 (15.7)                   |               |
| 70–99            | 2785 (8.3)                  | 2785 (8.3)                    |               |
| Gender, n (%)    |                             |                               | 1.000         |
| Male             | 15023 (44.8)                | 15023 (44.8)                  |               |
| Female           | 18532 (55.2)                | 18532 (55.2)                  |               |
| Diabetes mellitus, n (%) |                 |                               | < 0.001      |
| Yes              | 3744 (11.2)                 | 1158 (3.5)                    |               |
| No               | 29811 (88.8)                | 32397 (96.5)                  |               |
| Hypertension, n (%) |                             |                               | < 0.001      |
| Yes              | 8044 (24)                   | 4205 (12.5)                   |               |
| No               | 25511 (76)                  | 29350 (87.5)                  |               |
| Obesity, n (%)   |                             |                               | < 0.001      |
| Yes              | 386 (1.2)                   | 42 (0.1)                      |               |
| No               | 33169 (98.8)                | 33513 (99.9)                  |               |
| COPD, n (%)      |                             |                               | < 0.001      |
| Yes              | 3472 (10.3)                 | 2597 (7.7)                    |               |
| No               | 30083 (89.7)                | 30958 (92.3)                  |               |
| Uremia, n (%)    |                             |                               | < 0.001      |
| Yes              | 283 (0.8)                   | 189 (0.6)                     |               |
| No               | 33272 (99.2)                | 33366 (99.4)                  |               |
| Aspirin use, n (%) |                             |                               | < 0.001      |
| Yes              | 4388 (13.1)                 | 2924 (8.7)                    |               |
| No               | 29167 (86.9)                | 30631 (91.3)                  |               |
| NSAIDs use, n (%) |                             |                               | < 0.001      |
| Yes              | 25852 (77)                  | 23302 (69.4)                  |               |
| No               | 7703 (23)                   | 10253 (30.6)                  |               |
| Metformin use, n (%) |                             |                               | < 0.001      |
| Yes              | 907 (2.7)                   | 529 (1.6)                     |               |
| No               | 32648 (97.3)                | 33026 (98.4)                  |               |
| Rosiglitazone use, n (%) |                  |                               | 0.002         |
| Yes              | 56 (0.2)                    | 27 (0.1)                      |               |
| No               | 33499 (99.8)                | 33528 (99.9)                  |               |
| Pioglitazone use, n (%) |                 |                               | 0.576         |
| Yes              | 43 (0.1)                    | 37 (0.1)                      |               |
| No               | 33512 (99.9)                | 33518 (99.9)                  |               |

\(^a\) Tested by the Chi-square test.
COPD: chronic obstructive pulmonary disease, as a proxy of smoking.
NSAIDs: nonsteroidal anti-inflammatory drugs.

Hyperlipidemia is associated with a higher subsequent risk of bladder cancer
The median follow-up time was not significantly different between the hyperlipidemia and non-hyperlipidemia cohorts (8.02 years vs. 7.96 years, \( P = 0.105 \)). The mean duration from the index date to the date of bladder cancer occurrence was not significantly different between the hyperlipidemia and non-hyperlipidemia cohorts (mean ± standard deviation: 5.31 ± 3.48 years vs. 4.67 ± 3.16 years, \( P = 0.116 \)).

During the 1–14 years of follow-up, the prevalence of bladder cancer in the hyperlipidemia cohort was significantly higher than that in the non-hyperlipidemia cohort (0.6% [217/33,555] vs. 0.4% [143/33,555], \( P < 0.001 \); Table 2). The relative risk of bladder cancer in the hyperlipidemia cohort was significantly higher than that in the non-hyperlipidemia cohort (unadjusted hazard ratio [HR] = 1.51, 95% confidence interval [CI] = 1.22–1.86, \( P < 0.001 \); Table 2). The trend remained the same after adjustment for the propensity score (adjusted HR = 1.37, 95% CI = 1.10–1.71, \( P = 0.005 \)) (Table 2).

### Table 2

The prevalence rate and relative risk of having bladder cancer in hyperlipidemia cohort compared to those in non-hyperlipidemia cohort

| Cohorts                        | Bladder cancer: n (%) | \( P \) value |
|-------------------------------|-----------------------|---------------|
| Hyperlipidemia (n = 33555)    | 217 (0.6)             | < 0.001<sup>a</sup> |
| Non-hyperlipidemia (n = 33555)| 143 (0.4)             |               |

| Cohorts                        | Un-adjusted hazard ratio | 95% confidence intervals | \( P \) value |
|-------------------------------|--------------------------|---------------------------|---------------|
| Hyperlipidemia (n = 33555)    | 1.51                     | 1.22–1.86                 | < 0.001<sup>b</sup> |
| Non-hyperlipidemia (n = 33555)| 1.00                    |                           |               |

| Cohorts                        | Adjusted hazard ratio    | 95% confidence intervals | \( P \) value |
|-------------------------------|--------------------------|---------------------------|---------------|
| Hyperlipidemia (n = 33555)    | 1.37                     | 1.10–1.71                 | 0.005<sup>#</sup> |
| Non-hyperlipidemia (n = 33555)| 1.00                    |                           |               |

<sup>a</sup> Tested by the Chi-squared tests

<sup>b</sup> Tested by Cox proportional hazard regression.

<sup>#</sup> Adjusted for propensity score.

**Men, but not women, with hyperlipidemia show a higher subsequent risk of bladder cancer**

Subgroup analyses were performed to evaluate the association between gender and the risk of bladder cancer between the hyperlipidemia and non-hyperlipidemia cohorts. Men in the hyperlipidemia cohort (n = 15,023) had a significantly higher subsequent risk of bladder cancer than did those in the non-hyperlipidemia cohort (n = 15,023) (adjusted HR = 1.36, 95% CI = 1.01–1.82, \( P = 0.040 \); Table 3). However, the subsequent risk of bladder cancer was not significantly different between women in the hyperlipidemia cohort and those in the non-hyperlipidemia cohort (both n = 18,532) (Table 3).
Table 3
The relative risk of having bladder cancer in hyperlipidemia cohort compared to that in non-hyperlipidemia cohort stratified by gender

| Cohort            | Unadjusted hazard ratio | 95% Confidence intervals | P value |
|-------------------|-------------------------|---------------------------|---------|
| Hyperlipidemia men| 1.54                    | 1.16–2.04                 | 0.003a  |
| Non-hyperlipidemia men | 1.00                  |                           |         |

| Cohort            | Adjusted hazard ratio | 95% confidence intervals | P value |
|-------------------|-----------------------|---------------------------|---------|
| Hyperlipidemia men| 1.36                  | 1.01–1.82                 | 0.040#  |
| Non-hyperlipidemia men | 1.00                 |                           |         |

Subgroup analyses were also performed to evaluate the association between gender and the risk of bladder cancer in the hyperlipidemia cohort. Notably, the prevalence of bladder cancer was significantly higher in men than in women in the hyperlipidemia cohort (0.8% [124/15,023] vs. 0.4% [98/18,532], P < 0.001). Men in the hyperlipidemia cohort also had a significantly higher subsequent risk of bladder cancer than did women in the hyperlipidemia cohort (adjusted HR = 1.97, 95% CI = 1.51–2.59, P < 0.001; Table 3).

**Hyperlipidemia increases the subsequent risk of bladder cancer in young adult men**

Subgroup analyses were also performed to evaluate the association between age and the risk of bladder cancer between the hyperlipidemia and the non-hyperlipidemia cohorts. In the age group of 20–39 years, the risk of bladder cancer was significantly higher in the hyperlipidemia cohort than that in the non-hyperlipidemia cohort (adjusted HR = 4.38, 95% CI = 1.23–15.62, P = 0.023; Table 4). Similar results were observed in the age group of 40–49 years (adjusted HR = 2.1, 95% CI = 1.11–3.95, P = 0.022; Table 4) but not in the age groups of 50–99 years (Table 4).
### Table 4
Subgroup analyses of the relative risk of having bladder cancer in hyperlipidemia cohort compared to that in non-hyperlipidemia cohort.

| Age groups | Hazard ratio Un-adjusted | 95% Confidence intervals | P value |
|------------|--------------------------|--------------------------|---------|
| Hyperlipidemia cohort vs. non-hyperlipidemia cohort |
| 20–39      | 5.32                     | 1.55-18.25               | 0.008a  |
| 40-49      | 2.13                     | 1.13-3.99                | 0.019a  |
| 50-59      | 1.39                     | 0.91-2.14                | 0.127a  |
| 60-69      | 1.14                     | 0.78-1.67                | 0.495#  |
| 70-99      | 1.25                     | 0.80-1.96                | 0.332a  |
| Hyperlipidemia men vs. non-hyperlipidemia men |
| 20–39      | 6.98                     | 1.59-30.72               | 0.010a  |
| 40-49      | 2.16                     | 0.97-4.83                | 0.061a  |
| 50-59      | 1.16                     | 0.63-2.15                | 0.631a  |
| 60-69      | 1.48                     | 0.86-2.54                | 0.157a  |
| 70-99      | 0.93                     | 0.53-1.63                | 0.791a  |
| Hyperlipidemia women vs. non-hyperlipidemia women |
| 20–39      | 1.99                     | 0.18-21.97               | 0.574a  |
| 40-49      | 2.02                     | 0.73-5.6                 | 0.178a  |
| 50-59      | 1.68                     | 0.93-3.06                | 0.087a  |
| 60-69      | 0.84                     | 0.49-1.45                | 0.535a  |
| 70-99      | 2.03                     | 0.9-4.57                 | 0.087a  |

a Tested by Cox proportional hazard regression.
# Adjusted for propensity score.

The subsequent risk of bladder cancer was further explored in analyses stratified by age in both men and women. The risk of bladder cancer was significantly higher in men aged 20–39 years in the hyperlipidemia cohort than in those in the non-hyperlipidemia cohort (HR = 5.45, 95% CI = 1.19-25.07, P = 0.029; Table 3). However, the risk of bladder cancer was not significantly different between men aged 40–99 years in the hyperlipidemia cohort and those in the non-hyperlipidemia cohort (Table 4). Moreover, in all age groups, the risk
of bladder cancer was not significantly different between women in the hyperlipidemia cohort and those in the non-hyperlipidemia cohort (Table 4).

**Discussion**

Data regarding the association between hyperlipidemia and cancer risk are heterogeneous.\(^{24}\) Higher risks of colon, prostate, and testicular cancers have been reported in patients with hyperlipidemia in previous research.\(^{24}\) By contrast, studies have reported that patients with hyperlipidemia have lower risks of stomach, liver, and hematopoietic/lymphoid tissue cancers.\(^{24}\) This population-based cohort study demonstrated that patients with hyperlipidemia exhibited a 37–51% increased risk of bladder cancer compared with their non-hyperlipidemia counterparts. The prevalence of hyperlipidemia is high in adults (37% for men and 40% for women).\(^{25}\) The data from this study thus should have profound clinical impact.

The association of hyperlipidemia with the risks of some types of cancer differs between men and women.\(^{24}\) A large population-based study (Metabolic syndrome and Cancer project) showed that hyperlipidemia has an inverse relationship with the risks of liver cancer, pancreas cancer, nonmelanoma of the skin, and lymph/hematopoietic tissue cancer among men and with the risks of gallbladder cancer, breast cancer, melanoma of the skin, and lymph/hematopoietic tissue cancer among women.\(^{26}\) In the present study, subgroup analyses revealed that men with hyperlipidemia had a 36–54% increased risk of bladder cancer compared with men without hyperlipidemia. Notably, the risk of bladder cancer was not significantly different between women with hyperlipidemia and women without hyperlipidemia. These data further highlight that hyperlipidemia increases the subsequent risk of bladder cancer in men but not in women. Therefore, gender has different impacts on the risk of cancer, including bladder cancer, in hyperlipidemia patients. The possible mechanisms may relate to the distinct body fat distribution and energy utilization patterns between men and women, and the storage of fat in visceral adipose tissue and visceral obesity in men have been linked to carcinogenesis.\(^{12,27}\)

Although bladder cancer is not defined as an endocrine-related cancer, the association of the androgen/androgen receptor with bladder cancer development has been reported.\(^{28}\) The androgen receptor has been found in bladder tissue, and the downregulation of androgen receptor expression suppresses bladder cancer growth in vitro and in vivo.\(^{28,29}\) Thus, the association between the androgen/androgen receptor and bladder cancer has been evaluated. Shiota et al demonstrated that androgen deprivation therapy decreases the risk of bladder cancer in patients with prostate cancer.\(^{30}\) In a prospective cohort study, finasteride, a 5-alpha reductase inhibitor that reduces the dihydrotestosterone level, was associated with a reduced incidence of bladder cancer.\(^{31}\) According to the findings of previous studies and our study, sex hormones may play a role in the different risks of bladder cancer in hyperlipidemia patients. Additional studies are required to ascertain the underlying mechanisms.

Subgroup analyses further revealed that young adult men aged 20–39 years in the hyperlipidemia cohort exhibited an up to 5.45-fold increased risk of bladder cancer compared with those in the non-hyperlipidemia cohort. However, the risk of bladder cancer was not significantly different between men aged older than 40 years in the hyperlipidemia cohort and those in the non-hyperlipidemia cohort. These data further highlight that hyperlipidemia increases the subsequent risk of bladder cancer, especially in young adult men. A hyperlipidemia diagnosis in young adults increases the subsequent risk of coronary heart disease due to the increased duration of exposure to hyperlipidemia.\(^{11}\) Cancer often takes years to be diagnosed after initial exposure to a carcinogen.\(^{32}\) Obesity and a high-fat, low-vegetable diet may represent risk factors for carcinogenesis.\(^{33}\) Adolescent obesity has been linked to an increased subsequent risk of cancer.\(^{34}\) Metabolic dysregulation in early life plays an integral role in carcinogenesis.\(^{34}\) The results of our study reveal that hyperlipidemia development in young adulthood (aged 20–39 years) increased the subsequent risk of bladder cancer. According to our finding, early-onset hyperlipidemia is a risk factor for bladder cancer in men.
According to previous studies, many factors influence the risk of bladder cancer. For example, DM is associated with an increased incidence and mortality of bladder cancer in both men and women.\(^\text{15}\) In patients on dialysis for end-stage renal disease, the risk of bladder cancer is increased and is higher in women.\(^\text{19}\) Obesity increases the risk of bladder cancer linearly according to the body mass index.\(^\text{17,35}\) COPD is associated with poor survival in elderly patients with bladder cancer.\(^\text{18}\) Female patients with hypertension are at an increased risk of bladder cancer,\(^\text{36}\) and untreated hypertension is associated with a decreased risk of bladder cancer.\(^\text{16}\) Aspirin is associated with a decreased recurrent risk of bladder cancer.\(^\text{20}\) NSAIDs, especially ibuprofen, and metformin are associated with reduced bladder cancer risk.\(^\text{21,22}\) Rosiglitazone and pioglitazone are associated with an increased risk of bladder cancer in patients with diabetes.\(^\text{23}\) In this study, the aforementioned confounders significantly differed between the two cohorts, except for pioglitazone. The impact of these confounders was controlled for through propensity score adjustment. After controlling for these potential confounders, the risk of bladder cancer was higher in the hyperlipidemia cohort than in the non-hyperlipidemia cohort and in men than in women in the hyperlipidemia cohort.

Our population-based study showed the association of hyperlipidemia with the risk of bladder cancer. Whether controlling the serum lipid level can prevent the risk of bladder cancer is unclear; further evaluation is thus required. Furthermore, this study has some limitations. First, smoking is a major risk factor for bladder cancer;\(^\text{5}\) this information is lacking in the NHIRD. Because smoking is the most important causative factor for COPD,\(^\text{37}\) we used COPD as a confounder to decrease the bias of this study. Second, the dietary factor is important for the risk of bladder cancer;\(^\text{38}\) information on lifestyle, physical activity, and dietary habits are lacking in the NHIRD. Third, data on the serum lipid level (such as low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides) are unavailable in the NHIRD. Fourth, direct evidence is lacking for the cause–effect relationship between hyperlipidemia and the risk of bladder cancer. Prospective randomized clinical trials should be conducted to obtain more precise information.

**Conclusions**

Hyperlipidemia increases the risk of bladder cancer in men but not in women. Young men (aged 20–39 years) with hyperlipidemia show a 5.45-fold increased risk of bladder cancer compared with men without hyperlipidemia.

**Declarations**

**Ethics approval and consent to participate**

This study was approved by the Institutional Review Board of Taipei Medical University (Protocol Number: N201803071). The study was performed in accordance with the Declaration of Helsinki.

**Availability of data and materials**

The data in this publication are commercially confidential. Data requests should be made to the Corresponding Author.

**Acknowledgments**

None.

**Conflicts of Interest**

None declared.
Sources of Funding

None.

Authorship

H.J.S, K.H.L, Y.C.W, Y.C.F, P.S.T and C.J.H have made substantial contributions to the conception of the work, data acquisition, data analysis and interpretation, drafting the work, reviewed the manuscript and final approval of the submitted version.

References

1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. European urology (Review) 2017; 71(1): 96-108; e-pub ahead of print 2016/07/03; doi 10.1016/j.eururo.2016.06.010.
2. Hung CF, Yang CK, Ou YC. Urologic cancer in Taiwan. Japanese journal of clinical oncology (Review) 2016; 46(7): 605-609; e-pub ahead of print 2016/04/08; doi 10.1093/jjco/hyw038.
3. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. The Journal of urology 2016; 196(4): 1021-1029; e-pub ahead of print 2016/06/19; doi 10.1016/j.juro.2016.06.049.
4. Feifer AH, Taylor JM, Tarin TV, Herr HW. Maximizing cure for muscle-invasive bladder cancer: integration of surgery and chemotherapy. European urology (Review) 2011; 59(6): 978-984; e-pub ahead of print 2011/01/25; doi 10.1016/j.eururo.2011.01.014.
5. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. Jama (Research Support, N.I.H., Intramural) 2011; 306(7): 737-745; e-pub ahead of print 2011/08/19; doi 10.1001/jama.2011.1142.
6. Nieder AM, Porter MP, Soloway MS. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. The Journal of urology (Comparative Study) 2008; 180(5): 2005-2009; discussion 2009-2010; e-pub ahead of print 2008/09/20; doi 10.1016/j.juro.2008.07.038.
7. Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nature genetics (Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural) 2010; 42(11): 978-984; e-pub ahead of print 2010/10/26; doi 10.1038/ng.687.
8. Hata Y, Nakajima K. Life-style and serum lipids and lipoproteins. Journal of atherosclerosis and thrombosis (Research Support, Non-U.S. Gov't Review) 2000; 7(4): 177-197; e-pub ahead of print 2001/08/28.
9. Hu J, La Vecchia C, de Groh M, Negri E, Morrison H, Mery L et al. Dietary cholesterol intake and cancer. Annals of oncology : official journal of the European Society for Medical Oncology (Research Support, Non-U.S. Gov't) 2012; 23(2): 491-500; e-pub ahead of print 2011/05/06; doi 10.1093/annonc/mdr155.
10. Montella M, Di Maso M, Crispo A, Grimaldi M, Bosetti C, Turati F et al. Metabolic syndrome and the risk of urothelial carcinoma of the bladder: a case-control study. BMC cancer (Research Support, Non-U.S. Gov't) 2015; 15: 720; e-pub ahead of print 2015/10/18; doi 10.1186/s12885-015-1769-9.
11. Navar-Boggan AM, Peterson ED, D'Agostino RB, Sr., Neely B, Sniderman AD, Pencina MJ. Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease. Circulation (Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.) 2015; 131(5): 451-458; e-pub ahead of print 2015/01/28; doi 10.1161/CIRCULATIONAHA.114.012477.
12. Varlamov O, Bethea CL, Roberts CT, Jr. Sex-specific differences in lipid and glucose metabolism. Frontiers in endocrinology (Review) 2014; 5: 241; e-pub ahead of print 2015/02/04; doi 10.3389/fendo.2014.00241.
13. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiology and drug safety (Research Support, Non-
U.S. Gov't) 2011; **20**(3): 236-242; e-pub ahead of print 2011/02/26; doi 10.1002/pds.2087.

14. Li YH, Ueng KC, Jeng JS, Charng MJ, Lin TH, Chien KL et al. 2017 Taiwan lipid guidelines for high risk patients. *Journal of the Formosan Medical Association = Taiwan yi zhi* (Review) 2017; **116**(4): 217-248; e-pub ahead of print 2017/03/01; doi 10.1016/j.jfma.2016.11.013.

15. Zhu Z, Zhang X, Shen Z, Zhong S, Wang X, Lu Y et al. Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies. *PloS one* (Meta-Analysis Research Support, Non-U.S. Gov't) 2013; **8**(2): e56662; e-pub ahead of print 2013/02/26; doi 10.1371/journal.pone.0056662.

16. Jiang X, Castelao JE, Yuan JM, Groshen S, Stern MC, Conti DV et al. Hypertension, diuretics and antihypertensives in relation to bladder cancer. *Carcinogenesis* (Comparative Study Research Support, N.I.H., Extramural) 2010; **31**(11): 1964-1971; e-pub ahead of print 2010/08/25; doi 10.1093/carcin/bgq173.

17. Qin Q, Xu X, Wang X, Zheng XY. Obesity and risk of bladder cancer: a meta-analysis of cohort studies. *Asian Pacific journal of cancer prevention : APJCP* (Meta-Analysis Research Support, Non-U.S. Gov't) 2013; **14**(5): 3117-3121; e-pub ahead of print 2013/06/28.

18. van de Schans SA, Janssen-Heijnen ML, Biesma B, Smeenk FW, van de Poll-Franse LV, Seynaeve C et al. COPD in cancer patients: higher prevalence in the elderly, a different treatment strategy in case of primary tumours above the diaphragm, and a worse overall survival in the elderly patient. *European journal of cancer* (Multicenter Study) 2007; **43**(15): 2194-2202; e-pub ahead of print 2007/09/22; doi 10.1016/j.ejca.2007.08.011.

19. Stewart JH, Buccianti G, Agodoo L, Gellert R, McCredie MR, Lowenfels AB et al. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. *Journal of the American Society of Nephrology : JASN* (Research Support, Non-U.S. Gov't) 2003; **14**(1): 197-207; e-pub ahead of print 2002/12/31.

20. Gee JR, Jarrard DF, Bruskewitz RC, Moon TD, Hedican SP, Levenson GE et al. Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guerin. *BJU international* 2009; **103**(6): 736-739; e-pub ahead of print 2008/11/15; doi 10.1111/j.1464-410X.2008.08123.x.

21. Baris D, Karagas MR, Koutrou S, Colt JS, Johnson A, Schwenn M et al. Nonsteroidal anti-inflammatory drugs and other analgesic use and bladder cancer in northern New England. *International journal of cancer* (Research Support, N.I.H., Extramural) 2013; **132**(1): 162-173; e-pub ahead of print 2012/04/17; doi 10.1002/ijc.27590.

22. El-Arabey AA. New insight for metformin against bladder cancer. *Genes and environment : the official journal of the Japanese Environmental Mutagen Society* (Review) 2017; **39**: 13; e-pub ahead of print 2017/04/05; doi 10.1186/s41021-017-0074-z.

23. Hsiao FY, Hsieh PH, Huang WF, Tsai YW, Gau CS. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case-control study. *Drug safety* 2013; **36**(8): 643-649; e-pub ahead of print 2013/06/26; doi 10.1007/s40264-013-0080-4.

24. Radisauskas R, Kuzmiene I, Miljakovic E, Everatt R. Hypertension, serum lipids and cancer risk: A review of epidemiological evidence. *Medicina* (Review) 2016; **52**(2): 89-98; e-pub ahead of print 2016/05/14; doi 10.1016/j.medici.2016.03.002.

25. Venkitaehalam L, Wang K, Porath A, Corbalan R, Hirsch AT, Cohen DJ et al. Global variation in the prevalence of elevated cholesterol in outpatients with established vascular disease or 3 cardiovascular risk factors according to national indices of economic development and health system performance. *Circulation* (Research Support, U.S. Gov't, Non-P.H.S.) 2012; **125**(15): 1858-1869; e-pub ahead of print 2012/04/12; doi 10.1161/CIRCULATIONAHA.111.064378.

26. Strohmaier S, Edlinger M, Manjer J, Stocks T, Bjorge T, Borena W et al. Total serum cholesterol and cancer incidence in the Metabolic syndrome and Cancer Project (Me-Ca). *PloS one* (Multicenter Study Research Support, Non-U.S. Gov't) 2013; **8**(1): e54242; e-pub ahead of print 2013/02/02; doi 10.1371/journal.pone.0054242.

27. Doyle SL, Donohoe CL, Lysaght J, Reynolds JV. Visceral obesity, metabolic syndrome, insulin resistance and cancer. *The Proceedings of the Nutrition Society* (Research Support, Non-U.S. Gov't) 2012; **71**(1): 181-189; e-pub ahead of print 2011/11/05; doi 10.1017/S000766551100320X.

28. Li P, Chen J, Miyamoto H. Androgen Receptor Signaling in Bladder Cancer. *Cancers* (Review) 2017; **9**(2); e-pub ahead of print 2017/03/01; doi 10.3390/cancers9020020.

29. Wu JT, Han BM, Yu SQ, Wang HP, Xia SJ. Androgen receptor is a potential therapeutic target for bladder
cancer. Urology (Research Support, Non-U.S. Gov't) 2010; 75(4): 820-827; e-pub ahead of print 2010/01/20; doi 10.1016/j.urology.2009.10.041.

30. Shiota M, Yokomizo A, Takeuchi A, Imada K, Kiyoshima K, Inokuchi J et al. Secondary bladder cancer after anticancer therapy for prostate cancer: reduced comorbidity after androgen-deprivation therapy. Oncotarget (Research Support, Non-U.S. Gov't) 2015; 6(16): 14710-14719; e-pub ahead of print 2015/04/23; doi 10.18632/oncotarget.3817.

31. Morales EE, Grill S, Svatke RS, Kaushik D, Thompson IM, Jr., Ankerst DP et al. Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study. European urology (Observational Study) 2016; 69(3): 407-410; e-pub ahead of print 2015/09/01; doi 10.1016/j.eururo.2015.08.029.

32. Lynch J, Smith GD. A life course approach to chronic disease epidemiology. Annual review of public health (Research Support, Non-U.S. Gov't Review) 2005; 26: 1-35; e-pub ahead of print 2005/03/12; doi 10.1146/annurev.publhealth.26.021304.144505.

33. Calle EE, Thun MJ. Obesity and cancer. Oncogene (Review) 2004; 23(38): 6365-6378; e-pub ahead of print 2004/08/24; doi 10.1038/sj.onc.1207751.

34. Yang YC, Johnson MP, Schorpp KM, Boen CE, Harris KM. Young Adult Risk Factors for Cancer: Obesity, Inflammation, and Sociobehavioral Mechanisms. American journal of preventive medicine 2017; 53(3): S21-S29; e-pub ahead of print 2017/08/19; doi 10.1016/j.amepre.2017.04.025.

35. Sun JW, Zhao LG, Yang Y, Ma X, Wang YY, Xiang YB. Obesity and risk of bladder cancer: a dose-response meta-analysis of 15 cohort studies. PloS one (Meta-Analysis Research Support, Non-U.S. Gov't Review) 2015; 10(3): e0119313; e-pub ahead of print 2015/03/25; doi 10.1371/journal.pone.0119313.

36. Kok VC, Zhang HW, Lin CT, Huang SC, Wu MF. Positive association between hypertension and urinary bladder cancer: epidemiologic evidence involving 79,236 propensity score-matched individuals. Upsala journal of medical sciences 2018; 123(2): 109-115; e-pub ahead of print 2018/06/19; doi 10.1080/03009734.2018.1473534.

37. Laniado-Laborin R. Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21 century. International journal of environmental research and public health (Review) 2009; 6(1): 209-224; e-pub ahead of print 2009/05/15; doi 10.3390/ijerph6010209.

38. Steinmaus CM, Nunez S, Smith AH. Diet and bladder cancer: a meta-analysis of six dietary variables. American journal of epidemiology (Meta-Analysis Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.) 2000; 151(7): 693-702; e-pub ahead of print 2001/02/07.

Figures
Figure 1

Flowchart of patient selection in the study cohort. LHID: Longitudinal Health Insurance Database.